Palvella Therapeutics, Inc. (PVLA)
NASDAQ: PVLA · Real-Time Price · USD
134.95
-0.54 (-0.40%)
At close: Mar 5, 2026, 4:00 PM EST
132.28
-2.67 (-1.98%)
After-hours: Mar 5, 2026, 7:46 PM EST
Palvella Therapeutics Stock Forecast
Stock Price Forecast
The 17 analysts with 12-month price forecasts for Palvella Therapeutics stock have an average target of 154.59, with a low estimate of 38 and a high estimate of 255. The average target predicts an increase of 14.55% from the current stock price of 134.95.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Palvella Therapeutics stock from 17 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 8 | 8 | 9 | 12 | 12 | 12 |
| Buy | 4 | 4 | 4 | 4 | 5 | 5 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 12 | 12 | 13 | 16 | 17 | 17 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Mizuho | Mizuho | Buy Maintains $205 → $250 | Buy | Maintains | $205 → $250 | +85.25% | Feb 25, 2026 |
| BTIG | BTIG | Strong Buy Maintains $192 → $215 | Strong Buy | Maintains | $192 → $215 | +59.32% | Feb 25, 2026 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $174 → $210 | Strong Buy | Maintains | $174 → $210 | +55.61% | Feb 24, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $200 → $255 | Strong Buy | Maintains | $200 → $255 | +88.96% | Feb 24, 2026 |
| BTIG | BTIG | Strong Buy Reiterates $192 | Strong Buy | Reiterates | $192 | +42.27% | Jan 29, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
27.20K
EPS This Year
-3.59
from -7.83
EPS Next Year
-3.95
from -3.59
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | n/a | 420,000 | ||||
| Avg | n/a | 27,203 | ||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -3.00 | -3.03 | ||||
| Avg | -3.59 | -3.95 | ||||
| Low | -3.61 | -4.95 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.